Schrodinger, Inc. - Common Stock (NQ:SDGR)

25.12 +0.62 (+2.53%)

Delayed Quote Updated: 9:46 AM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

MarketBeat Week in Review – 3/6 - 3/10

March 11, 2023

Stocks are down sharply to end the week, and the MarketBeat staff continues to show investors why dividend stocks need to be part of your playbook

Via MarketBeat

Topics Artificial Intelligence Economy

Analyst Expectations for Schrodinger's Future ↗

March 10, 2023

Via Benzinga

3 Amazing AI Stocks for Your March Buy List ↗

March 09, 2023

With the Street catching onto the transformational power of AI, these amazing AI stocks are very well-positioned to climb tremendously.

Via InvestorPlace

Why Shares of Schrödinger Were Up Today ↗

March 01, 2023

The company delivered a nice earnings surprise.

Via The Motley Fool

Citigroup Maintains Buy Rating for Schrodinger: Here's What You Need To Know ↗

January 31, 2023

Via Benzinga

4 Analysts Have This to Say About Schrodinger ↗

January 31, 2023

Via Benzinga

Schrodinger is an AI-Powered Drug Discovery Developer to Watch

March 08, 2023

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

Via MarketBeat

Topics Artificial Intelligence

Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

March 01, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 28, 2023

Via Benzinga

Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results

February 28, 2023

From Schrödinger, Inc.

Via Business Wire

3 AI Stocks to Buy for the Future of Automation ↗

February 17, 2023

Increased appreciation for AI and the Street's reduced hostility to growth stocks make this a good time to find AI stocks to buy.

Via InvestorPlace

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 17, 2023

From Schrödinger, Inc.

Via Business Wire

Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda

February 14, 2023

From Schrödinger Inc.

Via Business Wire

Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28

February 13, 2023

From Schrödinger

Via Business Wire

Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development ↗

February 04, 2023

Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a...

Via Talk Markets

Schrödinger to Present at SVB Securities Global Biopharma Conference

January 31, 2023

From Schrödinger

Via Business Wire

Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million ↗

January 21, 2023

Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in...

Via Talk Markets

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 20, 2023

From Schrödinger

Via Business Wire

Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

January 09, 2023

From Schrödinger, Inc.

Via Business Wire

Why These 7 Healthcare Stocks Could Soar in 2023 ↗

January 02, 2023

These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.

Via InvestorPlace

7 Drug Stocks That Will Soar in 2023 ↗

December 22, 2022

These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.

Via InvestorPlace

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 16, 2022

From Schrödinger, Inc.

Via Business Wire

Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗

December 13, 2022

Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.

Via Benzinga

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting

December 12, 2022

From Schrödinger

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

December 05, 2022

During Monday's session, 49 companies made new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 28, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 02, 2022

On Friday, 72 companies hit new 52-week lows.

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.